臨床泌尿器科65巻5号

2011年04月発行

セミナー 泌尿器科医に必要なPET検査の知識―有用性と問題点・6

精巣腫瘍とPET検査

著者： 佐澤陽¹ 篠原信雄¹ 安部崇重¹ 丸山覚¹ 野々村克也¹

所属機関： ¹北海道大学大学院医学研究科腎泌尿器外科学分野

ページ範囲：P.297 - P.302

文献概要

要約　精巣腫瘍においては，治療前の正確な病期診断および化学療法後のviable細胞の有無評価がその後の治療を考えるうえで必要となる。正確な病期診断の点では，小病変の検出の観点からPETの有用性はCTを上回る結果は得られていない。治療後の残存病変でのviable細胞の評価については，非セミノーマ症例ではmature teratomaでは集積しないため有用性が示されていない。一方，セミノーマ症例では残存病変のviable細胞の評価において有用性が示されている。

参考文献

1）Krege S, Beyer J, Souchon R, et al：European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer：A report of the second meeting of the European Germ Cell Cancer Consensus group（EGCCCG）：Part Ⅰ. Eur Urol 53：478-496, 2008

2）Goethals I, Vriendt CD, Hoste P, et al：Normal uptake of F-18 FDG in the testis as assessed by PET/CT in a pediatric study population. Ann Nucl Med 23：817-820, 2009

3）von Rohr L, Klaeser B, Joerger M, et al：Increased pulmonary FDG uptake in Bleomycin-associated pneumonitis. Onkologie 30：320-323, 2007

4）Albers P, Bender H, Yilmaz H, et al：Positron emission tomography in the clinical staging of patients with stage Ⅰ and Ⅱ testicular germ cell tumors. Urology 53：808-811, 1999

fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89：549-556, 2002

Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high risk, clinical stage Ⅰ nonseminomatous germ cell tumors：preliminary report of MRC Trial TE22-the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25：3090-3095, 2007

F］-FDG-PET in clinical stage Ⅰ/Ⅱ non-seminomatous germ cell tumours：results of the German multicentre trial. Ann Oncol 19：1619-1623, 2008

8）Puc HS, Heelan R, Mazumdar M, et al：Management of residual mass in advanced seminoma：results and recommendations from the Memorial SloanKettering Cancer Center. J Clin Oncol 14：454-460, 1996

9）Flechon A, Bompas E, Biron P, et al：Management of post-chemotherapy residual masses in advanced seminoma. J Urol 168：1975-1979, 2002

fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma：an update of the prospective multicentric SEMPET trial. J Clin Oncol 22：1034-1039, 2004

11）Lewis DA, Tann M, Kesler K, et al：Positron emission tomography scans in postchemotherapy seminoma patients with residual masses：a retrospective review from Indiana University Hospital. J Clin Oncol 24：e54-e55, 2006

12）Krege S, Beyer J, Souchon R, et al：European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer：A report of the second meeting of the European Germ Cell Cancer Consensus group（EGCCCG）：Part Ⅱ. Eur Urol 53：497-513, 2008

13）Hartmann JT, Schmoll HJ, Kuczyk MA, et al：Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8：531-538, 1997

14）Oechsle K, Hartmann M, Brenner W, et al：German Multicenter Positron Emission Tomography Study Group：［18F］Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy. J Clin Oncol 26：5930-5935, 2006